🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsOral GLP-1 AgonistsOrforglipron Phase 3 ATTAIN-1 topline — need advice Page 3

Orforglipron Phase 3 ATTAIN-1 topline — need advice

TomFromTexas Wed, Jun 12, 2024 at 6:21 PM 14 replies 1,996 viewsPage 3 of 3
LibrarianMeg
Senior Member
1,678
7,890
Mar 2024
Baltimore, MD
Jun 17, 2024 at 2:12 AM#11
Dr.GastroMayo said:
The gap between trial results and real-world results is consistent and it is not fraud.

Agreed, and one caution: a single measurement is not a measurement. Anything that moves day to day needs a trend before it means anything at all.

Last edited: Jun 17, 2024 at 4:12 AM
43 18Dr.NateNeph, PharmD_Rodriguez, julia.endo and 40 others
Reply Quote Save Share Report
mark_tokyo
Member
456
1,890
Jun 2024
Tokyo, JP
Jun 19, 2024 at 5:39 PM#12
fiona_VT said:
The manufacturing argument is the underrated one.

Genuinely useful, thank you. I had the facts and not the framework. Taking it to my next appointment.

Last edited: Jun 19, 2024 at 8:39 PM
42 17bri_stats, pete_manc_UK, anna.melb_AU and 39 others
Reply Quote Save Share Report
TomTeleRx
Member
189
678
Feb 2025
Delaware
Jun 22, 2024 at 9:07 AM#13
Dr.GastroMayo said:
The gap between trial results and real-world results is consistent and it is not fraud.

This is where I part company with the consensus forming above. I would add the less popular caveat: these trial populations under-represented several groups, older adults and the highest BMI categories among them. The results probably generalise, and "probably" should be stated as an assumption rather than dropped.

41 16LibrarianMeg, bri_stats, pete_manc_UK and 38 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
josh_phd_bmore
Member
389
1,678
Jul 2024
Baltimore, MD
Jun 25, 2024 at 12:36 AM#14

Adding the numbers, since they settle part of this. For anyone reading later: the numbers in this thread are worth checking against a primary source before you act on them, including mine. Half the figures circulating in this community trace back to a secondary summary that dropped a qualifier.

Worth separating that from the trial evidence, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.

40 15KarenAZ_mom, zoe_NC, Dr.ObesityLA and 37 others
Reply Quote Save Share Report
Admin
Administrator
2,456
9,812
Oct 2023
Online
Jun 27, 2024 at 4:07 PM#15

Moderator note: reminder that nothing in this thread is medical advice, and that clinical claims need a source. Carry on.

39 14PeptideSynthNJ, Dr.KarenChen, Dr.NateNeph and 36 others
Reply Quote Save Share Report

Similar Threads

Orforglipron Phase 3 ATTAIN-1 topline — oral non-peptide GLP-116 replies
Oral semaglutide 50mg (Rybelsus HD) — OASIS program results12 replies
Danuglipron BID dosing — Pfizer oral GLP-1 update7 replies
Oral vs injectable GLP-1: bioavailability and efficacy comparison5 replies
Orforglipron food interaction profile — no fasting requirement15 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register